MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...
The FDA has expanded the approval of belimumab to include pediatric patients 5 to 17 years of age with active lupus nephritis. The Food and Drug Administration (FDA) has expanded the approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results